TY - JOUR
T1 - Targeted nutritional intervention for patients with mild cognitive impairment
T2 - The cognitive impairment study (CARES) trial 1
AU - Power, Rebecca
AU - Nolan, John M.
AU - Prado-Cabrero, Alfonso
AU - Coen, Robert
AU - Roche, Warren
AU - Power, Tommy
AU - Howard, Alan N.
AU - Mulcahy, Ríona
N1 - Funding Information:
This research was funded by the Howard Foundation (Registered UK Charity Number: 285822). The authors thank Michael Kirby (University Hospital Waterford, Waterford, Ireland) for his contribution to the consensus panel. The authors also thank Catherine Kelly and Lisa O?Brien (Whitfield Pharmacy, Waterford, Ireland) for the management of the trial supplements and Eurofins Biomnis (Dublin, Ireland) for performing the additional biochemical assessments for the trial.
Funding Information:
Funding: This research was funded by the Howard Foundation (Registered UK Charity Number: 285822).
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020
Y1 - 2020
N2 - Omega-3 fatty acids (ω-3FAs), carotenoids, and vitamin E are important constituents of a healthy diet. While they are present in brain tissue, studies have shown that these key nutrients are depleted in individuals with mild cognitive impairment (MCI) in comparison to cognitively healthy individuals. Therefore, it is likely that these individuals will benefit from targeted nutritional intervention, given that poor nutrition is one of the many modifiable risk factors for MCI. Evidence to date suggests that these nutritional compounds can work independently to optimize the neurocognitive environment, primarily due to their antioxidant and anti-inflammatory properties. To date, however, no interventional studies have examined the potential synergistic effects of a combination of ω-3FAs, carotenoids and vitamin E on the cognitive function of patients with MCI. Individuals with clinically confirmed MCI consumed an ω-3FA plus carotenoid plus vitamin E formulation or placebo for 12 months. Cognitive performance was determined from tasks that assessed global cognition and episodic memory. Ω-3FAs, carotenoids, and vitamin E were measured in blood. Carotenoid concentrations were also measured in tissue (skin and retina). Individuals consuming the active intervention (n = 6; median [IQR] age 73.5 [69.5–80.5] years; 50% female) exhibited statistically significant improvements (p < 0.05, for all) in tissue carotenoid concentrations, and carotenoid and ω-3FA concentrations in blood. Trends in improvements in episodic memory and global cognition were also observed in this group. In contrast, the placebo group (n = 7; median [IQR] 72 (69.5–75.5) years; 89% female) remained unchanged or worsened for all measurements (p > 0.05). Despite a small sample size, this exploratory study is the first of its kind to identify trends in improved cognitive performance in individuals with MCI following supplementation with ω-3FAs, carotenoids, and vitamin E.
AB - Omega-3 fatty acids (ω-3FAs), carotenoids, and vitamin E are important constituents of a healthy diet. While they are present in brain tissue, studies have shown that these key nutrients are depleted in individuals with mild cognitive impairment (MCI) in comparison to cognitively healthy individuals. Therefore, it is likely that these individuals will benefit from targeted nutritional intervention, given that poor nutrition is one of the many modifiable risk factors for MCI. Evidence to date suggests that these nutritional compounds can work independently to optimize the neurocognitive environment, primarily due to their antioxidant and anti-inflammatory properties. To date, however, no interventional studies have examined the potential synergistic effects of a combination of ω-3FAs, carotenoids and vitamin E on the cognitive function of patients with MCI. Individuals with clinically confirmed MCI consumed an ω-3FA plus carotenoid plus vitamin E formulation or placebo for 12 months. Cognitive performance was determined from tasks that assessed global cognition and episodic memory. Ω-3FAs, carotenoids, and vitamin E were measured in blood. Carotenoid concentrations were also measured in tissue (skin and retina). Individuals consuming the active intervention (n = 6; median [IQR] age 73.5 [69.5–80.5] years; 50% female) exhibited statistically significant improvements (p < 0.05, for all) in tissue carotenoid concentrations, and carotenoid and ω-3FA concentrations in blood. Trends in improvements in episodic memory and global cognition were also observed in this group. In contrast, the placebo group (n = 7; median [IQR] 72 (69.5–75.5) years; 89% female) remained unchanged or worsened for all measurements (p > 0.05). Despite a small sample size, this exploratory study is the first of its kind to identify trends in improved cognitive performance in individuals with MCI following supplementation with ω-3FAs, carotenoids, and vitamin E.
KW - Ageing
KW - Antioxidant
KW - Carotenoids
KW - Cognition
KW - Episodic memory
KW - Mild cognitive impairment
KW - Nutrition
KW - Older adults
KW - Omega-3 fatty acids
KW - Vitamin E
UR - http://www.scopus.com/inward/record.url?scp=85086160722&partnerID=8YFLogxK
U2 - 10.3390/jpm10020043
DO - 10.3390/jpm10020043
M3 - Article
AN - SCOPUS:85086160722
SN - 2075-4426
VL - 10
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
IS - 2
M1 - 43
ER -